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Abstract  
The need for increased sleep after traumatic brain injury is a common and disabling 
complaint, yet its etiology is unknown. Previous studies have demonstrated diffuse damage 
to various hypothalamic systems, but the integrity of the histaminergic tuberomammillary 
nucleus, a major arousal-promoting system located in the posterior hypothalamus, has never 
been examined in head trauma patients. Here, we demonstrate that severe head trauma is 
associated with a marked loss (41%) of histaminergic neurons. Reduced histamine signaling 
may contribute to increased sleep need, and therapies that enhance histaminergic tone may 
improve arousal after head trauma or other conditions. 
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Introduction 
Traumatic brain injury (TBI) is the leading cause of mortality and disability among 
young individuals in high-income countries,1 and the incidence has steadily increased over 
the last decade.2 As advances in the treatment of TBI have improved survival3, management 
of the chronic consequences of TBI has become a growing medical challenge.  
Among these chronic sequelae, sleep-wake disorders are especially common, 
particularly disturbances of arousal such as excessive daytime sleepiness and pleiosomnia 
(increased sleep need per 24 hours).4,5 Posttraumatic insomnia also can occur, although a 
prospective study using polysomnography and actigraphy reported a prevalence of only 5%.4 
Sleep-wake disturbances occur in 30-40% of TBI patients, but therapies to improve arousal 
after TBI are very limited.6 
Surprisingly little is known about injury to the hypothalamus and other wake-
promoting brain regions in TBI, but in a pilot study of 4 TBI patients and 4 controls without 
head injury, we found a 27% loss of wake-promoting orexin (hypocretin) neurons.7 To 
improve our understanding of injury to wake-promoting circuitry in TBI, we have now 
examined the hypothalamus after TBI in a larger number of subjects, with an additional focus 
on histaminergic neurons of the tuberomammillary nucleus (TMN). 
 
Materials and Methods 
 Human subjects. We obtained brains from 12 subjects with TBI from the 
Neuropathology Departments of Graz and Linz, Austria. Since trauma-induced pathological 
changes may not be apparent in the acute period after head trauma, we included only 
patients who survived at least 7 days after TBI. We examined hypothalamic tissue from the 
optic chiasm rostrally, back through several millimeters caudal to the posterior edge of the 
mammillary body. In addition, we studied hypothalami from 16 control subjects without TBI or 
other neurological disease, provided by the Neuropathology Departments of Beth Israel 
Deaconess Medical Center (n=10) and Graz, Austria (n=6). Controls died from myocardial 
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infarction or acute heart failure (n=7), pneumonia (n=2), acute renal failure (n=2), pulmonary 
embolism (n=1), upper gastrointestinal bleeding (n=1), colon perforation (n=1), pericarditis 
(n=1) and acute pancreatitis (n=1). Patients or controls with a history of previous TBI, known 
sleep-wake disturbances or evidence of neurological or psychiatric disease prior to TBI were 
not considered for this study. The local ethics committees of all involved institutes approved 
the study protocol. 
Brain tissue processing and immunohistochemistry. All hypothalami were fixed in 
10% buffered formalin and stored at 4°C. The mean fixation times of TBI and control brains 
were similar and varied from 1 month to 2 years. Immunohistochemical studies were focused 
on hypothalamic systems involved in the regulation of sleep and wake, including the neurons 
producing histamine, melanin-concentrating hormone (MCH) and orexin A. We identified 
histamine-producing neurons by immunostaining for histidine decarboxylase (HDC), the main 
enzyme responsible for the production of histamine. We used methods identical to those 
recently described.8  
To examine the pattern and severity of neuronal damage, axonal injury and gliosis 
within the hypothalamus, we used hematoxylin and eosin (H&E) and glial fibrillary acidic 
protein (GFAP) staining. To quantify gliosis, we measured the density of GFAP-
immunoreactive astrocytes (soma) as described in Fig. 2. 
Stereological cell counts. We used the same stereological methods as previously 
described.8  
Statistics. Group data are reported as means and standard deviations (SD). We 
established that data were normally distributed using the Kolmogorov-Smirnov test. 
Therefore, we compared cell counts between groups using Student’s t test and performed 
correlation analyses using the Pearson test. To assess whether the severity of cell loss 
differentially affected the examined neuronal populations, we applied ANOVA statistics 
followed by Bonferroni correction tests. Statistical significance was accepted at p<0.05. 
Page 4 of 16
John Wiley & Sons
Annals of Neurology
5 
 
 
Results 
 Clinical characteristics. The 12 TBI patients and the 16 controls did not differ by age 
(70±13 vs. 68±12 years, p=0.64) or gender (male/female ratio: 9/3 vs. 9/7, p=0.27). 
Postmortem delay (PMD; the interval between death and autopsy) tended to be longer in the 
TBI group (29.8±26.2 vs. 19.1±7.3 hours, p=0.19), but PMD did not correlate with the 
numbers of HDC, MCH or orexin A neurons. The TBI patients had closed head injury from 
traffic accidents (n=5) or falls (n=7), were comatose at hospital admission, and died in the 
intensive care unit with a mean survival after trauma of 27±28 days (range: 7–85 days). We 
did not find any correlation between duration of TBI survival and cell counts of HDC (r=-0.61, 
p=0.14), MCH (r=-0.16, p=0.73) and orexin (r=-0.13, p=0.79). 
General neuropathological findings. H&E staining did not reveal any abnormalities in 
the hypothalamus of all 16 controls and in 5 TBI patients. The remaining 7 TBI patients had a 
variety of findings, including acute hemorrhage, microglial nodules, rarefaction of neuropil, 
macrophage infiltration near disrupted white matter tracts, infarct, and axonal swellings (Fig. 
1). Three TBI patients had minor acute hemorrhages in the lateral hypothalamic area, lateral 
tuberomammillary nucleus, medial forebrain bundle, or cerebral peduncle as well as nearby 
regions including the putamen, globus pallidus, nucleus basalis of Meynert, or ventral 
anterior thalamic nucleus. The other four TBI patients showed more chronic patterns of injury 
with axonal swellings, loss of neuropil, and microglial nodules. Overall, the neuropathological 
abnormalities tended to be more prominent in the posterior than in the anterior part of the 
hypothalamus. The density of activated astrocytes indicating TBI-induced reactive gliosis, as 
assessed by GFAP immunostaining, was most pronounced around the border of the third 
ventricle. In this region, we observed gliosis even in hypothalamic tissue of controls, but in 
TBI patients, the density of activated astrocytes was higher and extended further into the 
hypothalamus than in controls (Fig. 2). 
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Loss of specific hypothalamic neuronal populations. The number of histaminergic 
neurons in TBI patients was reduced by 41% compared to controls (71,837±8,787 vs. 
122,290±12,064, p<0.001) (Fig. 3, 4). Asymmetry of HDC cell counts between left and right 
hypothalami was significantly higher in TBI patients than in controls (11.7±6.8% vs. 
4.5±3.3%, p=0.008), suggesting focal and asymmetric injury. In the TBI group, left-right 
asymmetry was positively correlated with more severe HDC cell loss (r=-0.68, p=0.03). In 
addition, loss of histaminergic neurons in TBI patients was significantly more pronounced in 
the posterior half of the TMN compared to the anterior half (48.8±22.9% vs. 32.3±21.7%, 
p=0.02). Compared to controls, TBI patients also had 29% fewer MCH neurons 
(58,232±8,944 vs. 82,054±12,834, p<0.001) and 21% fewer orexin A neurons (49,830±9,851 
vs. 62,935±8,704, p=0.001). The HDC neuron loss was significantly greater than the MCH 
and orexin A neuron loss (p=0.048 and p<0.001, respectively), whereas the 29% MCH and 
21% orexin A neuron loss was of similar magnitude (p=0.29). There was no significant left-
right asymmetry of MCH and orexin-A neurons in either group, and loss of MCH and orexin A 
neurons in TBI patients did not show any significant rostro-caudal difference.  
 
Discussion 
Excessive sleepiness and pleiosomnia are common after TBI, and we found a 41% 
loss of the wake-promoting histaminergic neurons in the TMN of patients with severe TBI. 
We also found moderate loss of the MCH (29%) and orexin A (21%) neurons as well as 
evidence of small hemorrhages, axonal injury, and gliosis in the hypothalamus. These 
findings demonstrate that severe TBI often injures the hypothalamus, and loss of specific 
wake-promoting neurons may contribute to increased sleep need.  
The observed pattern of cell loss suggests that with severe TBI, hypothalamic injury 
may be greatest in the most posterior parts. Of the examined neuronal populations, the TMN 
neurons showed the greatest cell loss, especially in the caudal half of the nucleus. The TMN 
is in the most posterior part of the hypothalamus, and it may be more susceptible to shearing 
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injury at the hypothalamus-midbrain junction. In contrast, the MCH and orexin A populations 
revealed less injury, perhaps because they are slightly further from the ventral surface of the 
hypothalamus.   
Histamine is a potent wake-promoting neurotransmitter, and loss of the histaminergic 
neurons may contribute to excessive daytime sleepiness and pleiosomnia after TBI. TMN 
neurons are mainly active during arousal and sustained wakefulness9-11, and their wake-
maintaining effect is clear from the sedating effects of centrally-acting antihistamines.12 In 
addition, mice lacking histidine decarboxylase have less wakefulness at the beginning of 
their active period and sleep more in a novel environment.13 The marked increase in 
histaminergic neurons in narcolepsy8,14  may be a compensatory response to the near-total 
loss of arousal-promoting orexin neurons,  and further emphasizes the importance of the 
histamine system in maintaining normal wakefulness. Pitolisant, a selective inverse agonist 
of the histamine H3 receptor, increases histamine signaling and improves sleepiness in 
narcolepsy patients.15 Thus, loss of histaminergic neurons in TBI may contribute to 
posttraumatic pleiosomnia, and increased sleep need may respond well to medications that 
enhance histamine signaling. 
The clinical significance of the observed 21% loss of hypocretin neurons remains 
unclear. In general, it is assumed that neurotransmitter signaling falls only with extensive cell 
loss, but a recent study shows that even a 14-23% reduction of nigral dopaminergic neurons 
suffices to cause mild Parkinsonism.16 Thus, the modest loss of orexin A neurons may also 
contribute to sleepiness, and could be another good therapeutic target once methods to 
improve hypocretin signaling become available.  
Interpreting the functional impact of the 29% loss of MCH neurons is more of a 
challenge as much less is known about the normal functions of this system. The MCH 
neurons probably promote sleep as they are active during REM sleep17, fire maximally during 
sleep18, and activation of these neurons increases both non-REM and REM sleep19, 20. Thus, 
it can be speculated that deficiency in MCH signaling potentially impairs recovery from TBI 
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by reducing sleep consolidation, but these effects were masked in our TBI population by their 
coma.   
A limitation of our study is the inclusion of only patients with severe TBI that resulted 
in persistent coma. Thus, we cannot comment on specific sleep disorders in these patients, 
and the loss of hypothalamic neurons may be more extreme than in patients with less severe 
head trauma. Also, factors linked to prolonged coma, secondary complications and 
differences in treatment prior to death could impact the observed neuropathology. Though it 
will be challenging, it would be ideal if future clinical-anatomical studies examined the brains 
of TBI patients with lengthy survival and well documented sleep-wake disturbances.   
In conclusion, we found that severe TBI substantially injures the histaminergic TMN 
neurons and moderately injures the orexin A and MCH neurons. Conventional H&E 
examination of the hypothalami from TBI patients showed acute and chronic lesions in 
several cases, but even those lacking H&E changes had loss of these neuropeptide-
producing neurons, suggesting that the extent of hypothalamic injury after TBI may be 
underestimated using conventional approaches. The discovery of injury to the TMN neurons 
may have important clinical and therapeutic implications for TBI and perhaps other conditions 
with increased sleep need. 
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Figure legends 
Figure 1 
Hematoxylin and eosin staining of hypothalamic tissue from traumatic brain injury patients  
reveals a spectrum of findings (arrows) including acute hemorrhage without organization (A),  
microglial nodules composed of lymphocytes and microglia (B), axonal swellings (C), and  
rarefaction of neuropil with macrophages (D).  
Figure 2 
Immunostaining for GFAP reveals more pronounced gliosis in TBI patients than in controls 
(A). The density of GFAP-immunoreactive soma is greatest near the wall of the third ventricle 
and basal meninges, especially in TBI patients. To quantify gliosis in TBI patients and 
controls, we stereotaxically counted GFAP immunoreactive soma within a 3x3mm box, 
divided into 10 layers of 300µm width. In each layer, we determined the mean cell density by 
counting the number of astrocytes in 10 randomly distributed counting boxes of 100x100µm. 
We measured this GFAP gradient from the medial wall of the third ventricle (green box) and 
from the ventral surface of the hypothalamus (blue box), in one section from the anterior 
hypothalamus and one from the posterior hypothalamus of each subject (B). *** p<0.001, ** 
p<0.01, * p<0.05 
Figure 3 
Photomicrographs illustrate the soma, proximal dendrites, and axons of immunolabeled 
HDC, MCH and orexin A neurons in TBI patients and control subjects. Compared to control 
subjects, TBI patients had 41% fewer histaminergic TMN neurons, 29% fewer MCH neurons, 
and 21% fewer orexin A neurons; *** p<0.001, ** p=0.01.  
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Figure 4 
Rostro-caudal distributions of histaminergic TMN neurons, MCH neurons and orexin A 
neurons in TBI patients and controls. TBI patients have the greatest loss of histaminergic 
neurons in the posterior half of the TMN. Loss of MCH neurons also tends to be higher in the 
posterior half of the MCH field (37.6±35.6% vs. 21.4±24.4%, p=0.12), while no rostro-caudal 
difference is observed in orexin A neurons (10.4±47.6% vs. 22.6±21.7%, p=0.28). 
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Figure 2  
Immunostaining for GFAP reveals more pronounced gliosis in TBI patients than in controls (A). The density 
of GFAP-immunoreactive soma is greatest near the wall of the third ventricle and basal meninges, especially 
in TBI patients. To quantify gliosis in TBI patients and controls, we stereotaxically counted GFAP 
immunoreactive soma within a 3x3mm box, divided into 10 layers of 300µm width. In each layer, we 
determined the mean cell density by counting the number of astrocytes in 10 randomly distributed counting 
boxes of 100x100µm. We measured this GFAP gradient from the medial wall of the third ventricle (green 
box) and from the ventral surface of the hypothalamus (blue box), in one section from the anterior 
hypothalamus and one from the posterior hypothalamus of each subject (B). *** p<0.001, ** p<0.01, * 
p<0.05  
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Figure 3  
Photomicrographs illustrate the soma, proximal dendrites, and axons of immunolabeled HDC, MCH and 
orexin A neurons in TBI patients and control subjects. Compared to control subjects, TBI patients had 41% 
fewer histaminergic TMN neurons, 29% fewer MCH neurons, and 21% fewer orexin A neurons; *** 
p<0.001, ** p=0.01.  
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Figure 4  
Rostro-caudal distributions of histaminergic TMN neurons, MCH neurons and orexin A neurons in TBI 
patients and controls. TBI patients have the greatest loss of histaminergic neurons in the posterior half of 
the TMN. Loss of MCH neurons also tends to be higher in the posterior half of the MCH field (37.6±35.6% 
vs. 21.4±24.4%, p=0.12), while no rostro-caudal difference is observed in orexin A neurons (10.4±47.6% 
vs. 22.6±21.7%, p=0.28).  
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